Since Mdm2 is overexpressed in colon carcinoma and other human cancers, targeting the Mdm2-p53 pathway could offer another promising target for sensitization of various human cancers to chemotherapeutic drugs [128]. This evidence concerns the gene TP53 and colon carcinoma.